SCHEMBL22556362

SCHEMBL22556362

O=C(NNC(=O)C1(CO)CC1)c1ccccc1Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 8/20 0.46
▸ ABCG2 Q9UNQ0 1/20 0.42
▸ MAPK8 P45983 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ YAP1 P46937 1/20 0.41
▸ TEAD4 Q15561 1/20 0.41
▸ TEAD2 Q15562 1/20 0.41
▸ MT-CO2 P00403 1/20 0.40
▸ SIRT2 Q8IXJ6 1/20 0.40
▸ PPARG P37231 1/20 0.40
▸ PPARD Q03181 1/20 0.40
▸ PPARA Q07869 1/20 0.40
▸ NR1H4 Q96RI1 1/20 0.40
▸ PTGS1 P23219 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ TAS2R14 Q9NYV8 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22556296 0.86 RXFP1 (0.44) RXFP1ABCG2MAPK8THRBMT-CO2
SCHEMBL22556300 0.85 RXFP1 (0.49) RXFP1ABCG2MAPK8THRBYAP1
SCHEMBL22571361 0.82 RXFP1 (0.41) RXFP1ABCG2MAPK8THRBSIRT2
SCHEMBL22556343 0.81 RXFP1 (0.48) RXFP1ABCG2MAPK8THRBMT-CO2
SCHEMBL23701615 0.81 RXFP1 (0.46) RXFP1ABCG2MAPK8THRBTAS2R14
SCHEMBL22556322 0.81 RXFP1 (0.45) RXFP1ABCG2MAPK8THRBPTGS1
SCHEMBL22556551 0.80 RXFP1 (0.46) RXFP1ABCG2MAPK8PTGS1SMN1; SMN2
SCHEMBL23701601 0.79 RXFP1 (0.47) RXFP1MAPK8MT-CO2PPARGPPARD
SCHEMBL30463763 0.78 RXFP1 (0.43) RXFP1ABCG2MAPK8THRBSIRT2
SCHEMBL22571350 0.78 RXFP1 (0.51) RXFP1ABCG2MAPK8YAP1TEAD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 — — US disclosed
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 — — US disclosed
US-20210238154-A1 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. 2021-08-05 — — US disclosed
US-20210238154-A1 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. 2021-08-05 — — US disclosed
EP-3793551-A1 OXADIAZOLE COMPOUNDS Vivace Therapeutics, Inc. (US) 2021-03-24 — — EP disclosed
WO-2019222431-A9 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2020-10-22 — — WO disclosed
WO-2019222431-A9 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2020-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238154-A1 OXADIAZOLE COMPOUNDS YAP1, TEAD2, TEAD3 RXFP1 3511/4885ABCG2 2985/4885MAPK8 986/4885
US-11661403-B2 Oxadiazole compounds YAP1, TEAD2, TEAD3 RXFP1 3511/4885ABCG2 2985/4885MAPK8 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback